US 11,752,137 B2
Ophthalmic compositions for treating ocular Demodex using lotilaner formulations
Bobak Robert Azamian, Newport Coast, CA (US); Douglas Michael Ackermann, Reno, NV (US); Shawn D. Hickok, Aliso Viejo, CA (US); and Joseph G. Vehige, Irvine, CA (US)
Assigned to Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed by Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed on Jul. 26, 2022, as Appl. No. 17/873,698.
Application 17/873,698 is a continuation of application No. 17/099,570, filed on Nov. 16, 2020, abandoned.
Application 17/099,570 is a continuation of application No. 16/221,390, filed on Dec. 14, 2018, granted, now 10,835,517, issued on Nov. 17, 2020.
Claims priority of provisional application 62/746,498, filed on Oct. 16, 2018.
Claims priority of provisional application 62/689,787, filed on Jun. 25, 2018.
Claims priority of provisional application 62/626,612, filed on Feb. 5, 2018.
Claims priority of provisional application 62/615,855, filed on Jan. 10, 2018.
Claims priority of provisional application 62/599,213, filed on Dec. 15, 2017.
Prior Publication US 2022/0354830 A1, Nov. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/422 (2006.01); A61P 27/02 (2006.01); A61K 9/48 (2006.01); A61K 47/26 (2006.01); A61P 33/14 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01)
CPC A61K 31/422 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01); A61P 33/14 (2018.01)] 20 Claims
OG exemplary drawing
 
1. An ophthalmic composition comprising lotilaner and a pharmaceutically acceptable vehicle,
wherein the ophthalmic composition is in eye drop form,
wherein the ophthalmic composition is sterile and nonirritating to the eye, and
wherein the lotilaner is present from about 0.10% to about 0.50% by weight with respect to the total weight of the composition.